Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
2024-04-11 06:20:37 ET Roche ( OTCQX:RHHBY ) and partner Eli Lilly ( NYSE: LLY ) have received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for their Elecsys pTau217 assay to support early diagnosis of Alzheimer's disease.... Read th...
2024-04-10 06:50:33 ET Summary Halozyme's ENHANZE technology drives growth, with Q4 2023 revenue up 27% YoY, projecting $915-$985 million in 2024. Key revenue from royalties, notably Darzalex Faspro, with a healthy financial state highlighted by a strong current ratio and stock re...
2024-04-10 05:49:03 ET Roche ( OTCQX:RHHBY ) has obtained CE Mark for its pre-diluted VENTANA HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx test.... Read the full article on Seeking Alpha For further details see: Roche companion diagnostic test wins CE Mark to i...
Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU PR Newswire Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2. 1 Patients with HE...
2024-04-09 11:30:10 ET Summary Today, we take a look at Novo Nordisk A/S, whose growth is being powered by Wegovy and Ozempic. The GLP-1 market is projected by some to grow to $100 billion by 2030 and Novo Nordisk is currently the preeminent player in this burgeoning space. Ho...
2024-04-09 11:00:51 ET More on Syros Pharmaceuticals Syros Pharmaceuticals, Inc. (SYRS) Q4 2023 Earnings Call Transcript Syros Pharmaceuticals: Rising Despite Dilution, A Must Look Syros Pharmaceuticals GAAP EPS of -$2.18 misses by $1.04, revenue of $0.4M misses by $...
2024-04-07 13:31:00 ET More on Merck, SPDR S&P Biotech ETF, etc. Merck: We Were Wrong, But The Exuberance Is Overly Done Here (Rating Upgrade) Merck: Better Times Ahead On Approvals And Outlook Merck's Future Brightens With Winrevair's Blockbuster Potential ...
2024-04-07 08:00:00 ET More on Phathom Pharmaceuticals Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Phathom Pharmaceuticals ...
2024-04-04 13:11:10 ET More on ADC Therapeutics ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade) ADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcript ADC Therapeutics SA 2023 Q4 - Results - Earnings Call Presentation Seeking A...
2024-04-01 10:17:11 ET More on Solid Biosciences Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid William Blair starts Solid Biosciences at outperform Piper Sandler upgrades Solid Biosciences to overweight Seeking Alpha’s Quant ...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
The obesity market has garnered much interest lately, ever since Novo Nordisk (NYSE: NVO) received FDA approval for its obesity drug Wegovy in 2021...
Thursday, Genentech, a unit of Roche Holdings AG (OTC:RHHBY), released results from the Phase 1b trial of CT-388, a dual GLP-1/GIP r...
– Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% (p < 0.001) – – At week 24, 100% of CT-388 treated participants achieved >5% weight loss, 70...